



PRESS RELEASE

Biosenta Announces First Tri-Filler Purchase Order

Toronto December 12, 2016. Biosenta Inc. announces it has received its first purchase order, for 8 metric tonnes, of its dry powder product, **Tri-Filler**. On November 15, 2016, Biosenta was awarded patents in the U.S. for Tri-Filler.

Tri-Filler prevents the growth of mold, bacteria, and viruses when embedded in paint, resins, plastics, drywall, and many other materials. It also enhances the structural strength and fire retardant properties of these materials, and unlike other anti-microbial agents, **Tri-Filler** is comprised of compounds that are safe for human consumption and are ecologically responsible.

In addition, Biosenta announces that on September 26, 2016 two directors, Messrs. David Butler and Edwin Korhonen, each received 121,857 shares as compensation for their services as board members.

About Biosenta Inc.

Biosenta Inc. develops and manufactures a range of chemical compounds for household and industrial applications using advanced encapsulated nanotechnology.

Other household disinfectants and cleaners possess similar levels of efficacy as traditional disinfectants. But Biosenta products contain significantly lower concentrations of active ingredients resulting in lower toxicity.

Biosenta disinfectants and cleaners will kill 99.9% of potentially deadly mold, fungi, bacteria and viruses on contact and prevent re-growth. Biosenta disinfectants are very safe due to the very low toxicity.

Biosenta industrial compounds are embedded to protect various materials, including drywall, plastic and resins, from microbe formation.

These compounds remain active for decades and protect the drywall of buildings, objects such as resin furniture, and carpet rubber backing and synthetic tufts which contain plastic or resin, as well as textiles and paper from mold, fungi, bacteria and viruses. Both the Biosenta household and industrial products are environmentally safe and biodegradable.

Disclaimer

The CSE has in no way passed upon the contents of this press release and further, has neither approved nor disapproved of the contents of this press release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Dene Rogers, President and CEO
Biosenta Inc.
3080 Yonge Street, Suite 6020
Toronto, ON M4N 3N1
Ph: 416-410 2019
Email: dene@biosenta.com